enGene Holdings Inc
NASDAQ:ENGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
enGene Holdings Inc
Total Liabilities
enGene Holdings Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Liabilities
$53.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Liabilities
CA$2.4m
|
CAGR 3-Years
55%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Liabilities
$170.3m
|
CAGR 3-Years
38%
|
CAGR 5-Years
25%
|
CAGR 10-Years
29%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Liabilities
$51.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
24%
|
CAGR 10-Years
33%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Liabilities
CA$4.1m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Total Liabilities
CA$75.8m
|
CAGR 3-Years
73%
|
CAGR 5-Years
54%
|
CAGR 10-Years
38%
|
|
enGene Holdings Inc
Glance View
enGene Holdings Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Saint-Laurent, Quebec and currently employs 2 full-time employees. The company went IPO on 2021-12-10. enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.
See Also
What is enGene Holdings Inc's Total Liabilities?
Total Liabilities
53.8m
USD
Based on the financial report for Oct 31, 2025, enGene Holdings Inc's Total Liabilities amounts to 53.8m USD.
What is enGene Holdings Inc's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
4%
Over the last year, the Total Liabilities growth was 39%. The average annual Total Liabilities growth rates for enGene Holdings Inc have been 4% over the past three years .
